CN1271070C - 用作腺苷A2α受体的配体的三唑基－咪唑并吡啶和三唑基嘌呤类的衍生物及其作为药物的应用 - Google Patents

用作腺苷A2α受体的配体的三唑基－咪唑并吡啶和三唑基嘌呤类的衍生物及其作为药物的应用 Download PDF

Info

Publication number
CN1271070C
CN1271070C CNB028138481A CN02813848A CN1271070C CN 1271070 C CN1271070 C CN 1271070C CN B028138481 A CNB028138481 A CN B028138481A CN 02813848 A CN02813848 A CN 02813848A CN 1271070 C CN1271070 C CN 1271070C
Authority
CN
China
Prior art keywords
compound
application
medicine
treatment
triazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028138481A
Other languages
English (en)
Chinese (zh)
Other versions
CN1525974A (zh
Inventor
G·塔齐亚
G·皮埃尔桑蒂
P·米内蒂
M·A·狄瑟塞尔
G·加洛
F·乔吉
L·乔吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of CN1525974A publication Critical patent/CN1525974A/zh
Application granted granted Critical
Publication of CN1271070C publication Critical patent/CN1271070C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB028138481A 2001-07-31 2002-07-25 用作腺苷A2α受体的配体的三唑基－咪唑并吡啶和三唑基嘌呤类的衍生物及其作为药物的应用 Expired - Fee Related CN1271070C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001RM000465A ITRM20010465A1 (it) 2001-07-31 2001-07-31 Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam
ITRM01A000465 2001-07-31

Publications (2)

Publication Number Publication Date
CN1525974A CN1525974A (zh) 2004-09-01
CN1271070C true CN1271070C (zh) 2006-08-23

Family

ID=11455703

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028138481A Expired - Fee Related CN1271070C (zh) 2001-07-31 2002-07-25 用作腺苷A2α受体的配体的三唑基－咪唑并吡啶和三唑基嘌呤类的衍生物及其作为药物的应用

Country Status (18)

Country Link
US (2) US7230102B2 (cg-RX-API-DMAC7.html)
EP (1) EP1412354B1 (cg-RX-API-DMAC7.html)
JP (1) JP4366186B2 (cg-RX-API-DMAC7.html)
KR (1) KR100884818B1 (cg-RX-API-DMAC7.html)
CN (1) CN1271070C (cg-RX-API-DMAC7.html)
AT (1) ATE325796T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002326146B2 (cg-RX-API-DMAC7.html)
BR (1) BR0211550A (cg-RX-API-DMAC7.html)
CA (1) CA2451279C (cg-RX-API-DMAC7.html)
DE (1) DE60211343T2 (cg-RX-API-DMAC7.html)
DK (1) DK1412354T3 (cg-RX-API-DMAC7.html)
ES (1) ES2263810T3 (cg-RX-API-DMAC7.html)
HU (1) HU228985B1 (cg-RX-API-DMAC7.html)
IT (1) ITRM20010465A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA04000886A (cg-RX-API-DMAC7.html)
PL (1) PL217269B1 (cg-RX-API-DMAC7.html)
PT (1) PT1412354E (cg-RX-API-DMAC7.html)
WO (1) WO2003011864A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105622495A (zh) * 2016-03-23 2016-06-01 叶芳 4-氯-3-硝基吡啶及其制备方法

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100883292B1 (ko) * 2001-06-29 2009-02-11 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ２ｂ 아데노신 수용체 길항제로서의 퓨린 유도체
ITRM20010465A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam
US7189730B2 (en) * 2001-12-18 2007-03-13 Cv Therapeutics, Inc. A2A adenosine receptor antagonists
CA2559036C (en) 2004-03-26 2013-08-20 Dainippon Sumitomo Pharma Co., Ltd. 9-substituted 8-oxoadenine compound
US8063063B2 (en) * 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
US8138172B2 (en) 2006-07-05 2012-03-20 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of TLR7
TW200831105A (en) 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
ES2373616T3 (es) 2007-03-19 2012-02-07 Astrazeneca Ab Compuestos de 8-oxo-adenina 9 sustituidos como moduladores del receptor de tipo toll (tlr7).
JP5480637B2 (ja) 2007-03-19 2014-04-23 アストラゼネカ・アクチエボラーグ Ｔｏｌｌ様受容体（ｔｌｒ７）モジュレーターとしての９−置換−８−オキソ−アデニン化合物
TW200902018A (en) * 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Novel adenine compound
HRP20130910T1 (hr) * 2007-03-20 2013-10-25 Curis, Inc. Kondenzirani aminopiridin kao inhibitori hsp90
WO2008114819A1 (ja) 2007-03-20 2008-09-25 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
JP5400763B2 (ja) * 2007-05-08 2014-01-29 アストラゼネカ・アクチエボラーグ 免疫調節特性を有するイミダゾキノリン類
PE20091156A1 (es) 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
JPWO2009091031A1 (ja) * 2008-01-17 2011-05-26 大日本住友製薬株式会社 アデニン化合物の製造方法
CA2711769A1 (en) 2008-01-17 2009-07-23 Dainippon Sumitomo Pharma Co. Ltd. Method for preparing adenine compound
TWI473614B (zh) * 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
US8846947B2 (en) 2008-07-03 2014-09-30 Glaxosmithkline Llc Benzimidazoles and related analogs as sirtuin modulators
AU2009274876C1 (en) 2008-07-23 2016-08-18 Kyowa Kirin Co., Ltd. Therapeutic agent for migraine
PT2408775E (pt) 2009-03-20 2015-08-05 Sigma Tau Ind Farmaceuti Derivados oxidados de triazolil purinas úteis como ligandos do recetor a2a de adenosina e a sua utilização como medicamentos
TWI398255B (zh) 2009-11-13 2013-06-11 Academia Sinica 結合至腺苷酸ａａ受體和腺苷酸轉運子以預防及治療神經退化疾病的雙功能化合物
WO2011068233A1 (en) * 2009-12-03 2011-06-09 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
WO2012070601A1 (ja) * 2010-11-24 2012-05-31 ヤマサ醤油株式会社 新規な２－アルキニル－ｎ９－プロパギルアデニンおよびその医薬用途
WO2012080728A1 (en) 2010-12-16 2012-06-21 Astrazeneca Ab Imidazo [4, 5 -c] quinolin- 1 -yl derivative useful in therapy
DK2651943T3 (en) 2010-12-17 2017-06-06 Sumitomo Dainippon Pharma Co Ltd purine derivatives
US9512120B2 (en) 2013-03-15 2016-12-06 Syngenta Participations Ag Microbicidally active imidazopyridine derivatives
US20190111069A1 (en) * 2016-04-15 2019-04-18 Oxford University Innovation Limited Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders
WO2025080645A1 (en) * 2023-10-10 2025-04-17 Regranion, Llc Methods and compositions for treating bullous pemphigoid
GB202319534D0 (en) * 2023-12-19 2024-01-31 Circadian Therapeutics Ltd Dosage regimen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990009178A1 (en) 1989-01-31 1990-08-23 Whitby Research, Inc. N6-substituted 9-methyladenines: a new class of adenosine receptor antagonists
US5670501A (en) * 1994-09-01 1997-09-23 Discovery Therapeutics, Inc. N-substituted 9-alkyladenines
EP1054012B1 (en) 1998-01-05 2003-06-11 Eisai Co., Ltd. Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes
GB9915437D0 (en) * 1999-07-01 1999-09-01 Cerebrus Ltd Chemical compounds III
KR100883292B1 (ko) * 2001-06-29 2009-02-11 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ２ｂ 아데노신 수용체 길항제로서의 퓨린 유도체
ITRM20010465A1 (it) 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105622495A (zh) * 2016-03-23 2016-06-01 叶芳 4-氯-3-硝基吡啶及其制备方法

Also Published As

Publication number Publication date
CA2451279C (en) 2011-05-10
EP1412354A1 (en) 2004-04-28
CN1525974A (zh) 2004-09-01
ES2263810T3 (es) 2006-12-16
HUP0401987A3 (en) 2012-12-28
US20040204428A1 (en) 2004-10-14
ATE325796T1 (de) 2006-06-15
DE60211343D1 (de) 2006-06-14
JP4366186B2 (ja) 2009-11-18
PL368409A1 (en) 2005-03-21
ITRM20010465A0 (it) 2001-07-31
US7230102B2 (en) 2007-06-12
KR20040023641A (ko) 2004-03-18
WO2003011864A1 (en) 2003-02-13
PL217269B1 (pl) 2014-06-30
CA2451279A1 (en) 2003-02-13
MXPA04000886A (es) 2004-06-03
DE60211343T2 (de) 2007-05-10
DK1412354T3 (da) 2006-09-18
US20070249638A1 (en) 2007-10-25
AU2002326146B2 (en) 2008-05-01
HU228985B1 (en) 2013-07-29
KR100884818B1 (ko) 2009-02-20
EP1412354B1 (en) 2006-05-10
ITRM20010465A1 (it) 2003-01-31
BR0211550A (pt) 2004-07-13
HK1068334A1 (en) 2005-04-29
HUP0401987A2 (hu) 2005-01-28
PT1412354E (pt) 2006-09-29
US7528252B2 (en) 2009-05-05
JP2005500355A (ja) 2005-01-06

Similar Documents

Publication Publication Date Title
CN1271070C (zh) 用作腺苷A2α受体的配体的三唑基－咪唑并吡啶和三唑基嘌呤类的衍生物及其作为药物的应用
CN1186324C (zh) 稠合杂芳基衍生物
CN1045778C (zh) 具有p*de－ⅳ抑制活性的新型化合物
CN1165537C (zh) 作为5-ht2c兴奋剂的吡咯并吲哚、吡啶并吲哚和氮杂�并吲哚
CN1263757C (zh) 特异于腺苷a1,a2a和a3受体的化合物及其应用
CN1278819A (zh) 作为促肾上腺皮质素释放激素拮抗剂、可用于治疗cns障碍和紧张相关性疾病的杂环基取代的环稠合吡啶和嘧啶
CN1161341C (zh) cGMP磷酸二酯酶的稠合吡啶并哒嗪抑制剂
CN1281458A (zh) 具有pde iv抑制活性的嘌呤化合物及其合成方法
CN1922185A (zh) 作为激酶抑制剂的吡唑并三嗪类化合物
CN1555374A (zh) 新的吡啶取代的吡唑并吡啶衍生物
CN1726216A (zh) C－6修饰的吲唑基吡咯并三嗪
CN1837207A (zh) 吡嗪并(氮杂)吲哚衍生物
CN1946405A (zh) 9h－嘌呤－2,6－二胺衍生物在治疗增殖性疾病中的应用以及新的9h－嘌呤－2,6－二胺衍生物
CN1694886A (zh) 作为周期素依赖性激酶抑制剂的咪唑并吡嗪
CN1328560A (zh) [1,2,4]三唑并[1,5－c]嘧啶衍生物
CN101076532A (zh) 作为甘氨酸转运体I(GlyT－1)抑制剂用于治疗阿尔茨海默氏病的二环和三环取代的苯甲酮化合物
CN1230184A (zh) 芳氨基稠合的吡啶和嘧啶
CN1047502A (zh) 8-取代黄嘌呤的制备方法
CN1538847A (zh) 4-氨基-6-苯基-吡咯并[2,3-d]嘧啶衍生物
CN1551881A (zh) 新颖二氢喋啶酮,其制备方法及作为药物组合物的用途
CN1882591A (zh) 具有PDE－5抑制活性的5,7－二氨基吡唑并[4,3－d]嘧啶
CN1404469A (zh) 2－氧代－1－吡咯烷衍生物、其制备方法和用途
CN1096784A (zh) 含取代4(5)-氨基-1,8-二氨杂萘的治疗剂
CN1030587A (zh) 2-(杂环烷基)咪唑并吡啶
CN1018614B (zh) 制备含n-杂环基-4-哌啶胺类的抗组胺组合物的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1068334

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060823

Termination date: 20140725

EXPY Termination of patent right or utility model